T4 RNA Ligase 1

Product Inquiry

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
ItolizumabT-1-hT; EQ-001; T-1-h; h-T1; Bmab-600ApprovedBiocon Ltd, Center Of Molecular Immunology, Biotech Pharmaceuticals Co LtdAlzumabIndiaPlaque psoriasisBiocon Ltd2013-01-01Dermatomyositis; Graft vs Host Disease; Lupus Erythematosus, Cutaneous; Coronavirus Disease 2019 (COVID-19); Lupus Nephritis; Respiratory Distress Syndrome, Adult; Psoriasis; Asthma; Plaque psoriasis
Details
  • Product Inquiry
  • Marketed Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland